Published in Br J Cancer on February 16, 2010
Extended Endocrine Therapy for Premenopausal Women With Breast Cancer | NCT00903162
Zoledronic acid inhibits aromatase activity and phosphorylation: potential mechanism for additive zoledronic acid and letrozole drug interaction. J Steroid Biochem Mol Biol (2012) 0.88
Zoledronic acid in breast cancer: latest findings and interpretations. Ther Adv Med Oncol (2011) 0.87
Basal and therapy-driven hypoxia-inducible factor-1α confers resistance to endocrine therapy in estrogen receptor-positive breast. Oncotarget (2015) 0.82
Probenecid as a sensitizer of bisphosphonate-mediated effects in breast cancer cells. Mol Cancer (2014) 0.77
Effects of letrozole on breast cancer micro-metastatic tumor growth in bone and lung in mice inoculated with murine 4T1 cells. Clin Exp Metastasis (2016) 0.77
Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study). PLoS One (2015) 0.76
Bones, breasts, and bisphosphonates: rationale for the use of zoledronic acid in advanced and early breast cancer. Breast Cancer (Dove Med Press) (2011) 0.75
Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med (2009) 13.74
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst (2005) 5.55
Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol (2001) 3.92
Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther (2001) 3.59
Cellular and molecular mechanisms of action of bisphosphonates. Cancer (2000) 3.57
Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev (2008) 2.17
The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer (2001) 2.14
Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol (2002) 2.03
Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst (2008) 1.87
Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res (1994) 1.84
Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens. Cancer Res (2003) 1.46
The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res (1998) 1.39
Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone (2001) 1.35
Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res (1992) 1.28
Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. J Urol (2003) 1.23
Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer (2005) 1.16
Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. Clin Cancer Res (2008) 1.10
New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects. Br J Cancer (2003) 1.10
Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro. Tumour Biol (2006) 1.05
Bone loss and the aromatase inhibitors. Br J Cancer (2005) 0.84
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet (2007) 8.08
The clinical course of bone metastases from breast cancer. Br J Cancer (1987) 4.93
A tabulated summary of the FDG PET literature. J Nucl Med (2001) 4.37
Physical and biological predictors of changes in whole-lung function following thoracic irradiation. Int J Radiat Oncol Biol Phys (1997) 3.17
FDG PET imaging in patients with pathologically verified dementia. J Nucl Med (2000) 2.70
The role of repeat uterine evacuation in the management of persistent gestational trophoblastic disease. Gynecol Oncol (2004) 2.31
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol (2007) 2.24
Mental stress--induced myocardial ischemia and cardiac events. JAMA (1996) 2.20
Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med (2001) 2.20
Pinhole collimation for ultra-high-resolution, small-field-of-view SPECT. Phys Med Biol (1994) 2.19
Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev (2008) 2.17
Regulation of stroke volume during submaximal and maximal upright exercise in normal man. Circ Res (1986) 2.15
The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer (2001) 2.14
Improved SPECT quantification using compensation for scattered photons. J Nucl Med (1984) 2.14
The skeletal metastatic complications of renal cell carcinoma. Int J Oncol (2001) 2.12
Performance characteristics of a whole-body PET scanner. J Nucl Med (1994) 2.08
Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. Am J Cardiol (1986) 2.07
Staging non-small cell lung cancer with whole-body PET. Radiology (1999) 2.07
Aromatase inhibitors in the adjuvant setting: bringing the gold to a standard? Cancer Treat Rev (2004) 2.05
Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography. Ann Neurol (1991) 2.05
Acute pulmonary embolism: artificial neural network approach for diagnosis. Radiology (1993) 1.96
Indium-111-labeled leukocytes for the localization of abscesses: preparation, analysis, tissue distribution, and comparison with gallium-67 citrate in dogs. J Lab Clin Med (1977) 1.87
Bayesian reconstruction and use of anatomical a priori information for emission tomography. IEEE Trans Med Imaging (1996) 1.87
Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood (2001) 1.83
Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol (2008) 1.80
Pylorus-preserving pancreatoduodenectomy. A clinical and physiologic appraisal. Ann Surg (1986) 1.74
Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res (1999) 1.73
Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer (2001) 1.70
Bone metastases and breast cancer. Cancer Treat Rev (1985) 1.67
Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res (2001) 1.67
Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol (1998) 1.64
Brain morphological changes and early marijuana use: a magnetic resonance and positron emission tomography study. J Addict Dis (2000) 1.63
Determinants of variable exercise performance among patients with severe left ventricular dysfunction. Am J Cardiol (1983) 1.62
[18F]2-fluoro-2-deoxyglucose-positron emission tomography correlation of gadolinium-enhanced MR imaging of central nervous system neoplasia. AJNR Am J Neuroradiol (1993) 1.62
Effect of age on the response of the left ventricular ejection fraction to exercise. N Engl J Med (1980) 1.61
Structural aspects of autophagy. Adv Exp Med Biol (1996) 1.61
Prognostic value of radionuclide angiography in medically treated patients with coronary artery disease. A comparison with clinical and catheterization variables. Circulation (1990) 1.61
Cardiac phantom evaluation of simultaneously acquired dual-isotope rest thallium-201/stress technetium-99m SPECT images. J Nucl Med (1993) 1.61
Indium-LLL labeled platelets: studies on preparation and evaluation of in vitro and in vivo functions. Thromb Res (1976) 1.61
Review of testing and use of adjuvant trastuzumab across a cancer network--are we treating the right patients? Clin Oncol (R Coll Radiol) (2010) 1.60
Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol (1997) 1.59
Evaluation of primary pulmonary carcinoid tumors using FDG PET. AJR Am J Roentgenol (1998) 1.59
Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer (2000) 1.56
Pulmonary abnormalities and PET data analysis: a retrospective study. Radiology (1997) 1.56
Temporal lobe hypometabolism on PET: predictor of seizure control after temporal lobectomy. Neurology (1993) 1.54
Adult age differences in the functional neuroanatomy of verbal recognition memory. Hum Brain Mapp (1999) 1.54
Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology (1993) 1.53
Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann Oncol (2011) 1.51
Cardiovascular and behavioral effects of aerobic exercise training in healthy older men and women. J Gerontol (1989) 1.51
Magnesium depletion in patients receiving cisplatin-based chemotherapy. Clin Oncol (R Coll Radiol) (2006) 1.50
FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. J Nucl Med (1993) 1.47
Gallium citrate Ga 67 imaging in patients with suspected inflammatory processes. Arch Surg (1975) 1.47
Dependence of hepatocytic autophagy on intracellularly sequestered calcium. J Biol Chem (1993) 1.46
Inverse Monte Carlo as a unified reconstruction algorithm for ECT. J Nucl Med (1986) 1.46
A randomized trial of low-dose heparin and intermittent pneumatic calf compression for the prevention of deep venous thrombosis after gynecologic oncology surgery. Am J Obstet Gynecol (1993) 1.44
Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer. Eur J Cancer (2004) 1.44
An evaluation of lesion detectability with cone-beam, fanbeam and parallel-beam collimation in SPECT by continuous ROC study. J Nucl Med (1994) 1.43
The management and clinical course of testicular seminoma: 15 years' experience at a single institution. Clin Oncol (R Coll Radiol) (1998) 1.43
Human herpesvirus 6 limbic encephalitis after stem cell transplantation. Ann Neurol (2001) 1.43
Non-selective autophagy. Semin Cell Biol (1990) 1.42
Neovascularization after transmyocardial laser revascularization in a model of chronic ischemia. Ann Thorac Surg (1998) 1.42
Evaluation of revised criteria for ventilation-perfusion scintigraphy in patients with suspected pulmonary embolism. Radiology (1994) 1.42
Accuracy of diagnosis of coronary artery disease by radionuclide management of left ventricular function during rest and exercise. Circulation (1981) 1.41
Advanced breast cancer: diagnosis and treatment. National Institute for Health and Clinical Excellence Guideline 2009 - an opportunity missed. Clin Oncol (R Coll Radiol) (2009) 1.39
Effects of meal size and correction technique on gastric emptying time: studies with two tracers and opposed detectors. J Nucl Med (1980) 1.38
Myocardial perfusion and ventricular function measurements during total coronary artery occlusion in humans. A comparison with rest and exercise radionuclide studies. Circulation (1994) 1.38
Sex-related differences in the normal cardiac response to upright exercise. Circulation (1984) 1.37
Splenectomy for primary and recurrent immune thrombocytopenic purpura (ITP). Current criteria for patient selection and results. Ann Surg (1987) 1.37
Preparation and evaluation of 111In-labeled leukocytes as an abscess imaging agent in dogs. Radiology (1976) 1.36
Indium-111 labeled leukocytes in the evaluation of suspected abdominal abscesses. Am J Surg (1980) 1.35
Arterial nicotine kinetics during cigarette smoking and intravenous nicotine administration: implications for addiction. Drug Alcohol Depend (1999) 1.32
Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. Ann Thorac Surg (1995) 1.31
MAGE, BAGE and GAGE: tumour antigen expression in benign and malignant ovarian tissue. Br J Cancer (1998) 1.30
Stress management and exercise training in cardiac patients with myocardial ischemia. Effects on prognosis and evaluation of mechanisms. Arch Intern Med (1997) 1.30
Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. J Nucl Med (1994) 1.30
Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. Cancer Res (1989) 1.30
An extravascular component of contrast enhancement in cranial computed tomography. Part II. Contrast enhancement and the blood-tissue barrier. Radiology (1975) 1.28
The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer (1998) 1.27
Scrub typhus: vector competence of Leptotrombidium chiangraiensis chiggers and transmission efficacy and isolation of Orientia tsutsugamushi. Ann N Y Acad Sci (2003) 1.27
Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Breast Cancer Res Treat (2004) 1.25
The anti-tumour activity of bisphosphonates. Cancer Treat Rev (2002) 1.25
Quantification of radiation-induced regional lung injury with perfusion imaging. Int J Radiat Oncol Biol Phys (1997) 1.24
Gastric emptying of varying meal weight and composition in man. Evaluation by dual liquid- and solid-phase isotopic method. Dig Dis Sci (1981) 1.24
Autoantibodies in chronic pulmonary tuberculosis. J Chronic Dis (1970) 1.24
Weekly epirubicin for breast cancer with liver metastases and abnormal liver biochemistry. Br J Cancer (1989) 1.21
Mental stress-induced ischemia in the laboratory and ambulatory ischemia during daily life. Association and hemodynamic features. Circulation (1995) 1.20
Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer (2003) 1.20
Optimum scanning protocol for FDG-PET evaluation of pulmonary malignancy. J Nucl Med (1995) 1.19
Chemotherapy for ovarian cancer--a consensus statement on standard practice. Br J Cancer (1998) 1.19
Prednisolone improves the response to primary endocrine treatment for advanced breast cancer. Br J Cancer (1988) 1.19
Metabolic effects of pamidronate in patients with metastatic bone disease. Br J Cancer (1996) 1.19
The utility of SPECT lung perfusion scans in minimizing and assessing the physiologic consequences of thoracic irradiation. Int J Radiat Oncol Biol Phys (1993) 1.17
Simultaneous compensation for attenuation, scatter and detector response for SPECT reconstruction in three dimensions. Phys Med Biol (1992) 1.16
From genetic abnormality to metastases: murine models of breast cancer and their use in the development of anticancer therapies. Breast Cancer Res Treat (2006) 1.15
Small-animal PET: advent of a new era of PET research. J Nucl Med (1999) 1.15